Ben N.
About Ben N.
Ben N. is the Principal Scientist and Biotherapeutics Mass Spectrometry Team Lead at Bristol Myers Squibb in California, with extensive experience in mass spectrometry and analytical characterization.
Current Role at Bristol Myers Squibb
Ben N. is currently employed at Bristol Myers Squibb as a Principal Scientist and Biotherapeutics Mass Spectrometry Team Lead. Based in California, United States, he leads efforts in mass spectrometry-based biotherapeutic analysis. His role involves managing high-throughput mass spectrometry platforms, integrating automation and machine learning to enhance sample and data handling capabilities.
Previous Roles at AstraZeneca
Between 2017 and 2022, Ben N. held several positions at AstraZeneca in Gaithersburg, Maryland. He began as Scientist I, then advanced to Scientist II / Analytical Characterization Lead from 2018 to 2020, and finally served as Senior Scientist / Analytical CMC Lead until 2022. Throughout his tenure, he focused on analytical characterization and CMC-related tasks for biotherapeutics.
Educational Background
Ben N. holds a Ph.D. in Mass Spectrometry, Biochemistry, and Bioinformatics from Washington University in St. Louis, completed from 2011 to 2017. Additionally, he earned a Master of Data Analytics from the University of Maryland Global Campus, studying Data Science, Business Intelligence, and Machine Learning from 2021 to 2023. His undergraduate Bachelor’s Degree in Applied Chemistry was obtained from East China University of Science and Technology from 2007 to 2011.
Technological Contributions
Ben N. has made significant technological contributions in his field. He developed a high-throughput, fully automated peptide mapping sample preparation procedure using Lynx, and created and implemented a machine learning model (XGBoost) to predict site-specific deamidations for antibodies in silico sequence liability. He has established high-throughput mass spectrometry platforms at Bristol Myers Squibb's San Diego site, enhancing sample and data handling capabilities.
Industry Collaboration and Representation
At Bristol Myers Squibb, Ben N. represents the company in the EFPIA 'MAM as a QC tool' inter-laboratory association. His work focuses on providing technical and regulatory considerations for implementing multi-attribute method (MAM) in a quality control environment. He has also contributed to cross-industry, inter-laboratory MAM technical forums through discussions and publications, furthering the adoption and improvement of MAM workflows.